Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.

"Competing interests: SP: scientific advisory income from: Amgen, AstraZeneca, Bristol Myers Squibb, Certis, Eli Lilly, Genentech, Illumina, Merck, Pfizer, Rakuten, and Tempus; SP’s university receives research funding from: Amgen, AstraZeneca/MedImmune, Bristol Myers Squibb, Eli Lilly, Fate Therapeutics, Iovance, Merck, Pfizer, Roche/Genentech, and SQZ Biotechnologies.TA-G has received research funding, honoraria, and non-financial or other support from IPSEN, Adacap, Pfizer, Sanofi, EISAI, Lilly, Bayer, Janssen, BMS, Astellas, Novartis, Roche, and Merck. SB: institutional grants: AstraZeneca and GlaxoSmithKline. Honoraria for Advisory boards: Amgen, AstraZeneca, Genmab, GlaxoSmithKline, Immunogen, Merck Sharp & Dohme, Merck Sereno, Mersana Therapeutics, OncXerna, Seagen, and Shattuck Labs; Honoraria for lectures: Amgen, AstraZeneca, Clovis, GlaxoSmithKline, Immunogen, Merck Sharp & Dohme, Mersana Therapeutics, Pfizer, and Roche. DW, JN, NES, DCP, L-YC, PK, MDH: employment by and stock ownership/options in AstraZeneca. MLA: former employment by and stock ownership/options in AstraZeneca. MD: employment by and stock ownership/options in AstraZeneca. JRD: institutional funds received from: AstraZeneca, Abbvie, Astellas, Gilead, Merck, Deciphera, Hutchison, BMS, Adlai Norte, Takeda, OnKure Therapeutics; Consulting: Gilead, OnKure Therapeutics; Equity Interest: OnKure Therapeutics. BAC: institutional research support: Astra Zeneca, Abbvie, Actuate Therapeutics, Astellas, Bayer, Dragonfly Therapeutics, Pfizer, Repare Therapeutics. Scientific advisory boards: Foundation Medicine, Tempus, Seattle Genetics, G1 therapeutics."

"Funding: This study was funded by AstraZeneca, Gaithersburg, MD, USA. Grant number is not applicable."

"Trial registration number NCT02671435."